Servier Presentations at ASCO 2026 Spotlight Expanding Rare Oncology Portfolio

Updated efficacy and safety data from a long-term analysis of the Phase 3 INDIGO trial of VORANIGO® (vorasidenib) will be presented in a rapid oral presentation Results from an ongoing Phase 1 trial evaluating investigational compound Emi-Le in adenoid cystic carcinoma will be shared in...